Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Friday, November 12, 2021 10:01:02 AM
Undoubtedly " he is equally disappointed but how can it be his fault the top-line data wasn’t met "
Amazing ignorance and theatrics over of "off with his head" because top-line was not met. If it failure of the top line in a clinical trial was deemed a "criminal" responsibility of the pharma CEO...there would be no Pharma Industry.
Bounty Hunters looking for Leo's head, and allegedly "screwed the pooch"...over the following statement in yesterday's PR:
When anyone reading the public information on the Trials Placebo/Brilacidin breakdown (both official CT sites and PR of the company) would KNOW...of the 120 patients included 60 received Brilacidin and 60 received SOC.
Hardly actionable...
Perhaps it could have been stated more clearly as...for those who know better, but wish to create an issue, where there is none.
"In the trial, 120 patients were treated, (and as CLEARLY STATED in the CT protocol, 60 receiving Placebo (SOC) and 60 receiving Brilacidin), with three-fourths of the Brilacidin administered patients receiving 5 days of study drug."
down 50%, but IMO Brilacidin still has too much opportunity in its pipeline to sell, especially with the pedigree behind Brilacidin in support of it's potential. I look forward to OM moving forward beginning Jan and 1st Quarter...
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM